Top Page
People's Insurance Co (Group) of China
(1339)
People's Insurance Co (Group) of China (1339) vs. iShares MSCI Hong Kong ETF (EWH)
People's Insurance Co (Group) of China Business Overview & Revenue Model
People's Insurance Co (Group) of China Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 576.06B | 549.16B | 501.76B | 475.09B | 592.01B | 579.77B |
| Gross Profit | 576.06B | 549.16B | 501.76B | 492.82B | 592.01B | 31.63B |
| EBITDA | 0.00 | 77.48B | 42.98B | 52.85B | 45.90B | 41.75B |
| Net Income | 46.71B | 42.87B | 22.77B | 25.37B | 21.48B | 20.04B |
Balance Sheet | ||||||
| Total Assets | 1.88T | 1.77T | 1.56T | 1.51T | 1.38T | 1.26T |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 664.26B | 21.87B | 21.36B | 21.79B | 23.13B |
| Total Debt | 41.51B | 52.60B | 40.26B | 46.20B | 47.43B | 60.34B |
| Total Liabilities | 1.49T | 1.40T | 1.23T | 1.21T | 1.08T | 982.51B |
| Stockholders Equity | 285.11B | 268.73B | 242.35B | 221.77B | 219.26B | 202.48B |
Cash Flow | ||||||
| Free Cash Flow | 88.51B | 83.59B | 66.98B | 65.08B | 110.35B | 59.83B |
| Operating Cash Flow | 92.79B | 87.99B | 70.55B | 71.65B | 72.73B | 31.87B |
| Investing Cash Flow | -98.88B | -77.60B | -70.93B | -73.28B | -81.56B | -51.37B |
| Financing Cash Flow | 12.05B | 4.86B | -11.48B | 8.56B | -35.86B | 21.11B |
People's Insurance Co (Group) of China Technical Analysis
People's Insurance Co (Group) of China Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $65.16B | 7.97 | 10.74% | 1.93% | 23.64% | 36.32% | |
78 Outperform | $389.16B | 6.31 | 17.34% | 3.00% | 9.40% | 79.93% | |
76 Outperform | $407.04B | 9.90 | 14.60% | 3.29% | 6.42% | 66.35% | |
75 Outperform | HK$202.54B | 4.72 | 34.37% | 5.72% | 49.90% | 203.77% | |
71 Outperform | €160.28B | 12.31 | 9.41% | 3.42% | 51.04% | 24.56% | |
70 Outperform | $352.34B | 5.36 | 18.41% | 3.69% | 15.08% | 23.13% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
People's Insurance Co (Group) of China Corporate Events
The People’s Insurance Company (Group) of China Limited has announced a board meeting scheduled for October 30, 2025, to review and approve the unaudited third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$7.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited has announced the scheduling of its 2025 second extraordinary general meeting (EGM) to be held on October 30, 2025. The meeting will address resolutions concerning the 2025 interim profit distribution and amendments to the authorization plan for the Board of Directors. This announcement is significant as it outlines key corporate governance actions that could impact shareholder value and company operations.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$7.20 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited announced an update to its interim dividend for the six months ended 30 June 2025, declaring a dividend of RMB 0.075 per share. The update includes details on the date of shareholders’ approval, Hong Kong share register information, and withholding tax arrangements. This announcement is significant for stakeholders as it provides clarity on the financial returns and tax implications for both resident and non-resident shareholders, potentially impacting investor decisions and market perception.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$7.20 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Co (Group) of China has announced the composition of its board of directors and the establishment of five special committees under the board. This organizational structure aims to enhance the company’s strategic direction, risk management, and governance, potentially strengthening its position in the insurance industry and improving stakeholder confidence.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$7.20 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited has announced the appointment of Mr. Xu Xiang as a non-executive director, effective from September 29, 2025, following approval from the National Financial Regulatory Administration. This strategic appointment, which also includes Mr. Xu’s roles in the Risk Management & Consumers’ Rights and Interests Protection Committee and the Nomination and Remuneration Committee, is expected to enhance the company’s governance and oversight capabilities, potentially strengthening its market position and stakeholder confidence.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$7.20 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited reported its unaudited interim financial results for the first half of 2025, showing a significant increase in total operating income to RMB 324,122 million, up from RMB 292,342 million in the same period of 2024. The company’s profit before tax rose to RMB 43,064 million, reflecting strong performance in insurance revenue and net investment gains, which could positively impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1339) stock is a Buy with a HK$7.30 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited announced an interim dividend of RMB 0.075 per share for the six months ended 30 June 2025, with a payment date set for 16 January 2026. This announcement reflects the company’s financial health and commitment to providing returns to its shareholders, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (HK:1339) stock is a Buy with a HK$7.30 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited has established a Nomination and Remuneration Committee under its Board of Directors to enhance the selection, appointment, and compensation management of its directors and senior management. This committee will assist in formulating procedures and criteria for appointments, conduct assessments of candidates, and oversee the implementation of remuneration and performance evaluation systems, thereby strengthening the company’s corporate governance structure.
The most recent analyst rating on (HK:1339) stock is a Buy with a HK$7.30 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited has established a Nomination and Remuneration Committee under its Board of Directors to enhance its governance structure. This committee is responsible for formulating procedures for selecting directors and senior management, assessing candidates, and developing remuneration and performance evaluation systems. The committee’s creation aims to improve the company’s management processes and ensure compliance with relevant laws and regulations, potentially strengthening its industry position and stakeholder confidence.
The most recent analyst rating on (HK:1339) stock is a Buy with a HK$7.30 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited has announced its plan to release its 2025 interim results on August 27, 2025, followed by a webcast presentation on August 28, 2025. The presentation will feature key company executives and provide an opportunity for investors to engage and have their questions addressed, reflecting the company’s commitment to transparency and investor relations.
The most recent analyst rating on (HK:1339) stock is a Buy with a HK$7.30 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.
The People’s Insurance Company (Group) of China Limited has announced a board meeting scheduled for August 27, 2025, to review and approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting could have significant implications for the company’s financial performance and shareholder returns, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1339) stock is a Hold with a HK$4.10 price target. To see the full list of analyst forecasts on People’s Insurance Co (Group) of China stock, see the HK:1339 Stock Forecast page.